All In Biotech

Drug Trial Radar · NCT03875729

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Phase 3 Randomized Double-Blind Multinational Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, a Humanized Fc Receptor (FcR) Non-Binding Anti-cluster of Differentiation 3 (CD3) Monoclonal Antibody, in Children and Adolescents With Newly Diagnosed Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 328 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

328

Actual

Start

Apr 5, 2019

Primary completion

May 1, 2023

Study completion May 1, 2023

Sponsor

Lead sponsor
Provention Bio, Inc.Industry
Sponsor type
Industry
First posted
Mar 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.. Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • teplizumabBiological

    Treatment

  • PlaceboBiological

    Control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)Time frame: Baseline to Week 78

Locations

62 sites in 9 countries. Site status is shown where the registry gives one.

  • Rady Children's Hospital-San Diego (Site 004)

    San Diego, California

  • UCSF Medical Center (Site 001)

    San Francisco, California

  • Diablo Clinical Research, Inc. (Site 002)

    Walnut Creek, California

  • University of Colorado-Barbara Davis Center for Childhood Diabetes (Site 005)

    Aurora, Colorado

  • Yale University of Medicine (Site 020)

    New Haven, Connecticut

  • UF Clinical and Translation Research Building (Site 015)

    Gainesville, Florida

  • Nemours Children's Specialty Care-Endocrinology (Site 047)

    Jacksonville, Florida

  • University of Miami Health System (Site 028)

    Miami, Florida

  • All Children's Hospital-Johns Hopkins Medicine (Site 048)

    St. Petersburg, Florida

  • University of South Florida Diabetes and Endocrinology Center (Site 011)

    Tampa, Florida

  • Atlanta Diabetes Associates (Site 009)

    Atlanta, Georgia

  • Centricity Research (Site 006)

    Columbus, Georgia

  • St. Luke's Children's Endocrinology (Site 052)

    Boise, Idaho

  • Rocky Mountain Diabetes and Osteoporosis Center (Site 007)

    Idaho Falls, Idaho

  • University of Chicago Medical Center (Site 017)

    Chicago, Illinois

  • Indiana University Hospital and Riley Hospital for Children (Site 014)

    Indianapolis, Indiana

  • U. Iowa Children's Hospital (Site 023)

    Iowa City, Iowa

  • Capital Diabetes & Endocrine Associates (Site 029)

    Camp Springs, Maryland

  • Baystate Pediatric Endocrinology & Diabetes (Site 040)

    Springfield, Massachusetts

  • U. Minnesota Health Clinical Research Unit (Site 031)

    Minneapolis, Minnesota

  • Children's Mercy Hospitals & Clinics (Site 026)

    Kansas City, Missouri

  • Washington University School of Medicine (Site 018)

    St Louis, Missouri

  • Women and Children's Hospital of Buffalo (Site 010)

    Buffalo, New York

  • UNC Hospitals Children's Specialty Clinic (Site 038)

    Chapel Hill, North Carolina

  • Rainbow Babies & Children's Hospital (Site 049)

    Cleveland, Ohio

  • Cleveland Clinic (Site 051)

    Cleveland, Ohio

  • Endocrinology Service Northwest, LLC (Site 034)

    Bend, Oregon

  • Childrens Hospital of Philadelphia - Endocrinology (Site 021)

    Philadelphia, Pennsylvania

  • Sanford Diabetes and Thyroiid Clinical (Site 013)

    Sioux Falls, South Dakota

  • AM Diabetes & Endocrinology Center (Site 008)

    Bartlett, Tennessee

  • Vanderbilt University Medical Center (Site 024)

    Nashville, Tennessee

  • Children's Medical Center Dallas (Site 033)

    Dallas, Texas

  • Benaroya Research Institute at Virginia Mason (Site 016)

    Seattle, Washington

  • MultiCare Institute for Research & Innovation (Site 003)

    Tacoma, Washington

  • CHU UCL Namur, site Clinique Sainte-Elisabeth (Site 205)

    Namur, Belgium

  • UZ Brussel - Campus Jette (Site 202)

    Brussels, Brussels Capital, Belgium

  • UZ Gent (Site 206)

    Ghent, Oost-Vlaanderen, Belgium

  • Alberta Diabetes Institute Clinical Research Unit Li Ka Shing Centre for Health Research Innovation (Site 103)

    Edmonton, Alberta, Canada

  • BC Diabetes (Site 102)

    Vancouver, British Columbia, Canada

  • Montreal Children's Hospital-McGill (Site 101)

    Montreal, Quebec, Canada

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.